INmune Bio Inc. INMB
1.03 USD +0.07 (+7.29%)
Regular-session close
1.05 +0.02 +2.07%
After hours · Nov 18, 4:00 PM ET
0.9236 Day range 1.07
0.893 52-week range 2.60
- YTD
- -33.97%
- 1 year
- -31.33%
News
benzinga.com Freedom Broker Maintains Buy on INmune Bio, Lowers Price Target to $2.5 Freedom Broker analyst Ilya Zubkov maintains INmune Bio (NASDAQ:INMB) with a Buy and lowers the price target from $4 to $2.5.
benzinga.com INmune Bio Q3 2026 Earnings Call Transcript INmune Bio (NASDAQ:INMB) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…benzinga.com INmune Bio Q3 EPS $(0.17) Misses $(0.15) Estimate INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 29.17 percent increase over losses of…
benzinga.com INmune Bio Submits Final Pre-Marketing Authorization Application Package To UK MHRA For Ebstrocel For Recessive Dystrophic Epidermolysis Bullosa; Expects Full MAA Submission In Early February 2027, With Potential UK Approval In Mid-2027; Has Engaged U.S. Regulatory Advisors With Rare Disease Expertise To Prepare And Submit A Type B Meeting Request To FDA INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation…
